JP2024517844A5 - - Google Patents

Info

Publication number
JP2024517844A5
JP2024517844A5 JP2023568105A JP2023568105A JP2024517844A5 JP 2024517844 A5 JP2024517844 A5 JP 2024517844A5 JP 2023568105 A JP2023568105 A JP 2023568105A JP 2023568105 A JP2023568105 A JP 2023568105A JP 2024517844 A5 JP2024517844 A5 JP 2024517844A5
Authority
JP
Japan
Prior art keywords
mbm
fab
mutations
amino acid
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517844A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/027413 external-priority patent/WO2022235628A1/en
Publication of JP2024517844A publication Critical patent/JP2024517844A/ja
Publication of JP2024517844A5 publication Critical patent/JP2024517844A5/ja
Pending legal-status Critical Current

Links

JP2023568105A 2021-05-04 2022-05-03 多重特異性fgf21受容体アゴニスト及びそれらの使用 Pending JP2024517844A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163183976P 2021-05-04 2021-05-04
US63/183,976 2021-05-04
US202263333293P 2022-04-21 2022-04-21
US63/333,293 2022-04-21
PCT/US2022/027413 WO2022235628A1 (en) 2021-05-04 2022-05-03 Multispecific fgf21 receptor agonists and their uses

Publications (2)

Publication Number Publication Date
JP2024517844A JP2024517844A (ja) 2024-04-23
JP2024517844A5 true JP2024517844A5 (enExample) 2025-05-14

Family

ID=81748993

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568105A Pending JP2024517844A (ja) 2021-05-04 2022-05-03 多重特異性fgf21受容体アゴニスト及びそれらの使用

Country Status (11)

Country Link
US (1) US20220372168A1 (enExample)
EP (1) EP4334353A1 (enExample)
JP (1) JP2024517844A (enExample)
KR (1) KR20240005823A (enExample)
AU (1) AU2022270075A1 (enExample)
BR (1) BR112023022878A2 (enExample)
CA (1) CA3219609A1 (enExample)
IL (1) IL308183A (enExample)
MX (1) MX2023012974A (enExample)
TW (1) TW202307007A (enExample)
WO (1) WO2022235628A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025157223A1 (en) * 2024-01-23 2025-07-31 Wuxi Biologics (Shanghai) Co., Ltd. Multispecific antibodies and uses thereof

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2128511C (en) 1992-01-23 2006-11-07 Andreas Pluckthun Monomeric and dimeric antibody-fragment fusion proteins
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
GB9720054D0 (en) 1997-09-19 1997-11-19 Celltech Therapeutics Ltd Biological products
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
PT1644412E (pt) 2003-07-01 2015-12-23 Ucb Biopharma Sprl Fragmentos de anticorpos fab modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
SI1680140T1 (sl) 2003-10-16 2011-08-31 Imclone Llc Inhibitorji receptorja-1 za fibroblastni rastni faktor in metode za zdravljenje z le-temi
AU2004309373A1 (en) 2003-12-22 2005-07-14 Amgen Inc. Methods for identifying functional antibodies
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
KR101374454B1 (ko) 2005-03-31 2014-03-17 추가이 세이야쿠 가부시키가이샤 회합제어에 의한 폴리펩티드 제조방법
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US8703132B2 (en) * 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
WO2012158704A1 (en) 2011-05-16 2012-11-22 Genentech, Inc. Fgfr1 agonists and methods of use
GB201218569D0 (en) 2012-10-16 2012-11-28 Mojo Maritime Ltd Improvements in or relating to marine operations
EA032681B1 (ru) * 2012-11-27 2019-07-31 Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ
MX385344B (es) 2012-11-28 2025-03-18 Zymeworks Bc Inc Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos.
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US10047167B2 (en) 2013-03-15 2018-08-14 Eli Lilly And Company Methods for producing fabs and bi-specific antibodies
TWI728373B (zh) * 2013-12-23 2021-05-21 美商建南德克公司 抗體及使用方法
RS60593B1 (sr) * 2014-01-24 2020-08-31 Ngm Biopharmaceuticals Inc Antitela koja vezuju domen 2 beta-kloto i postupci za njihovu upotrebu
EP3107565A4 (en) * 2014-02-21 2017-08-23 Regeneron Pharmaceuticals, Inc. Methods, compositions and kits for cell specific modulation of target antigens
MX373805B (es) * 2014-03-25 2020-03-24 Regeneron Pharma Agonistas de receptor fgf21 y usos del mismo.
US10428155B2 (en) * 2014-12-22 2019-10-01 Xencor, Inc. Trispecific antibodies
DK3277725T3 (da) 2015-03-30 2021-01-11 Regeneron Pharma Konstante tungkædeområder med reduceret binding til FC-gammareceptorer
EP3315511A1 (en) * 2016-10-29 2018-05-02 Miltenyi Biotec GmbH Adapter chimeric antigen receptor expressing cells for targeting of multiple antigens
AU2017356317A1 (en) * 2016-11-14 2019-05-30 Amgen Inc. Bispecific or biparatopic antigen binding proteins and uses thereof
KR20190136076A (ko) * 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
CN121591910A (zh) * 2017-11-21 2026-03-03 诺华股份有限公司 针对肿瘤相关抗原的三特异性结合分子及其用途
US10918667B2 (en) * 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
AU2020379735A1 (en) * 2019-11-05 2022-05-26 Regeneron Pharmaceuticals, Inc. N-terminal SCFV multispecific binding molecules

Similar Documents

Publication Publication Date Title
JP2026016376A5 (enExample)
JP2022553830A5 (enExample)
TWI576353B (zh) 多重特異性抗體
EP3421500B1 (en) Method for expressing and preparing an antibody fusion protein
EP1709081A2 (en) Fusion polypeptides capable of activating receptors
EP3418305B1 (en) Bivalent bispecific antibody hybrid protein expression and preparation methods
CN1461344A (zh) 多价靶结合蛋白
JP6674028B2 (ja) モノクローナル抗体組成物中のアフコシル化種の調節
JP2025016538A5 (enExample)
JP2024537779A5 (enExample)
Han et al. Naturally split intein Npu DnaE mediated rapid generation of bispecific IgG antibodies
JP2017501165A (ja) 脂肪組織の集積を処置するための組成物および方法
JP2023532129A5 (enExample)
WO2020135556A1 (zh) 抗体融合蛋白、制备方法及其应用
JP2023094613A (ja) 部位特異的抗体コンジュゲーション及びその使用
AU2023275542A1 (en) Methods for the treatment of kidney diseases or disorders
CN118063620A (zh) 双特异性抗体
JP2022518282A5 (enExample)
TWI911155B (zh) 藉由多肽鏈交換活化之治療性多特異性多肽
JP2022516439A5 (enExample)
EP3371297A1 (en) Methods for modulating production profiles of recombinant proteins in perfusion mode
US20220073610A1 (en) Bivalent bispecific antibody and prepartion method thereof, coding gene, host cell and composition
CN114805584B (zh) 抗原结合蛋白及其用途
JP2025514763A5 (enExample)
US20260042854A1 (en) Anti-glp-1r antibodies and uses thereof